The specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases has announced its results for the year ended 30 June 2020. The period reported and beyond has been one of strong progress for the Company and includes a licensing deal for its FLT3+Aurora kinase inhibitor programme, strong pre-clinical progress for its Selective TYK2/JAK1 Inhibitors in Autoimmune Diseases and Cancer as well as a grant application t
13 Oct 2020
Potential inflection points from all programmes in the months ahead
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Potential inflection points from all programmes in the months ahead
Sareum Holdings plc (SAR:LON) | 11.0 -0.4 (-24.1%) | Mkt Cap: 7.89m
- Published:
13 Oct 2020 -
Author:
Derren Nathan -
Pages:
9
The specialist drug development Company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases has announced its results for the year ended 30 June 2020. The period reported and beyond has been one of strong progress for the Company and includes a licensing deal for its FLT3+Aurora kinase inhibitor programme, strong pre-clinical progress for its Selective TYK2/JAK1 Inhibitors in Autoimmune Diseases and Cancer as well as a grant application t